Lead Product(s) : Dusquetide
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Soligenix Begins Phase 2 Trial of SGX945 for Behçet’s Disease Treatment
Details : SGX945 (dusquetide) is a peptide, P62 inhibitor administered intravenously via infusion, which is being investigated for treating Aphthous Ulcers in Behçet's Disease.
Product Name : SGX945
Product Type : Peptide
Upfront Cash : Inapplicable
November 14, 2024
Lead Product(s) : Dusquetide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dusquetide
Therapeutic Area : Rare Diseases and Disorders
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Fast Track Designation for Dusquetide for Oral Lesions of Behçet's Disease
Details : SGX945 (dusquetide) is an innate defense regulator (IDR), a new class of short, synthetic peptides. It is being evaluated in IND enabling studies for the treatment of oral lesions of Behçet's Disease.
Product Name : SGX945
Product Type : Peptide
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : Dusquetide
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dusquetide
Therapeutic Area : Rare Diseases and Disorders
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Fast Track Designation to Dusquetide for Oral Lesions in Behcet's Disease
Details : SGX945 (dusquetide) is an innate defense regulator (p62 protein modulator), a new class of short, synthetic peptides. It is being evaluated for the treatment of lesions of Behçet's Disease
Product Name : SGX945
Product Type : Peptide
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : Dusquetide
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dusquetide
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SGX945 (dusquetide) is a peptide inhibitor administered intravenously via infusion, which is being investigated for treating Aphthous Ulcers in Behçet's Disease.
Product Name : SGX945
Product Type : Peptide
Upfront Cash : Inapplicable
November 30, 2023
Lead Product(s) : Dusquetide
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dusquetide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Soligenix Announces European Patent Grant for Use of Dusquetide in Oral Mucositis
Details : SGX942 (dusquetide) is an innate defense regulator (IDR), short synthetic peptides, which modulates the body's reaction to both injury and infection towards an anti-inflammatory, anti-infective and tissue healing response in conditions like oral mucositi...
Product Name : SGX942
Product Type : Peptide
Upfront Cash : Inapplicable
May 16, 2023
Lead Product(s) : Dusquetide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dusquetide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
Details : SGX942 (dusquetide), an innate defense regulator demonstrated positive results in reducing tumor size in both preclinical and clinical studies, also has received Fast Track Designation from the FDA for the treatment of oral mucositis.
Product Name : SGX942
Product Type : Peptide
Upfront Cash : Inapplicable
April 01, 2022
Lead Product(s) : Dusquetide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dusquetide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Soligenix Completes Enrollment in Phase 3 DOM-INNATE Trial of SGX942 to Treat Oral Mucositis
Details : Soligenix has completed patient enrollment in its Phase 3 DOM-INNATE ("Dusquetide treatment in Oral Mucositis – by modulating INNATE Immunity") study for SGX942 (dusquetide) in the treatment of oral mucositis (OM) in head and neck cancer (HNC) patients...
Product Name : SGX942
Product Type : Peptide
Upfront Cash : Inapplicable
June 24, 2020
Lead Product(s) : Dusquetide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dusquetide
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Soligenix Gains Japanese Dusquetide Patent Allowance in Oral Mucositis
Details : The new claims cover therapeutic use of dusquetide (active ingredient in SGX942) and related innate defense regulator (IDR) analogs.
Product Name : SGX942
Product Type : Peptide
Upfront Cash : Inapplicable
March 02, 2020
Lead Product(s) : Dusquetide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable